Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostate Cancer Metastatic × Abiraterone Acetate × Clear all

Phase

Phase 4 1 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15 Prostatic Neoplasms, Castration-Resistant 2 Neoplasms 2 Metastatic Castration-resistant Prostate Cancer 2 Prostate Cancer Metastatic 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasm Metastasis 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistent Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Breast Neoplasms 1 Abiraterone Acetate 1

Interventions

enzalutamide 2 cabazitaxel 2 Prednisone 2 Androgen Antagonists 2 fludrocortisone acetate 1 darolutamide 1 XRP6258 1 Radiosurgery 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hydrocortisone 1 Granulocyte Colony-Stimulating Factor 1 Docetaxel 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡